Clinical Trials Browser

Completed × Paclitaxel × Endocrine × Clear all

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT00193531 2023-04-11

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Phase 2 Completed

Carcinoma, Neuroendocrine

NCT00004089 2013-07-10

Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer

Phase 2 Completed

EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00667641 2011-05-10

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Phase 1 Completed

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT00005647 2010-06-10

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Phase 1 Completed

CNSEndocrineHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic